{"product_id":"autl-business-model-canvas","title":"(AUTL) Autolus Therapeutics plc Business Model Canvas Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAutolus Therapeutics: Business Model Canvas in Focus\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore how Autolus Therapeutics plc builds value through innovative cell therapies, strategic partnerships, and a focused biopharma model. This concise Business Model Canvas breaks down the company’s key activities, revenue logic, and cost drivers in a clear, actionable format. Get the full version to uncover deeper strategic insights and make smarter decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePartnerships\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGMP cell therapy manufacturers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAutolus Therapeutics plc relies on GMP cell therapy manufacturers to run patient-specific autologous T-cell workflows: leukapheresis, gene transfer, expansion, and release testing. That matters after AUCATZYL’s U.S. approval in 2024, because each batch is one patient’s dose, so clinical supply and commercial scale-up depend on validated GMP slots, quality control, and cold-chain handoff.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialist leukemia and lymphoma centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAutolus Therapeutics plc works with specialist leukemia and lymphoma centers because its pipeline spans 3 hard-to-treat blood cancers: acute lymphoblastic leukemia, peripheral T-cell lymphoma, and multiple myeloma. These therapies are delivered in hospital-based hematology-oncology sites, where expert teams handle trial enrollment, cell therapy logistics, and patient monitoring.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trial networks in US and Europe\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAutolus Therapeutics plc relies on US and European clinical trial networks to recruit acutely ill patients into multicenter Phase 1 and Phase 2 studies, especially across adult and pediatric oncology centers. These links speed enrollment, improve data quality, and support the regulatory evidence base needed for cell therapy approvals.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCell-therapy logistics providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAutologous CAR-T needs strict chain-of-identity and cold-chain control from leukapheresis to infusion, so Autolus Therapeutics plc depends on cell-therapy logistics providers to cut spoilage and keep patient slots on schedule. These partners help move time-sensitive material fast and safely across collection, manufacturing, and return.\u003c\/p\u003e\n\u003cp\u003eFor a therapy where one missed handoff can delay treatment, specialized logistics reduces scheduling risk and protects manufacturing capacity. It also supports on-time delivery for each patient-specific batch.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eChain-of-identity is essential\u003c\/li\u003e\n\u003cli\u003eCold-chain handling lowers spoilage\u003c\/li\u003e\n\u003cli\u003eScheduling risk stays lower\u003c\/li\u003e\n\u003cli\u003ePatient slots need tight timing\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRegulators and reimbursement stakeholders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAutolus Therapeutics plc works with the FDA, MHRA, and other regulators to secure approvals and manage post-marketing follow-up for AUCATZYL, which was FDA approved in November 2024. Hospital reimbursement and payer access are just as critical, because one CAR-T infusion can cost over $400,000 before care costs, so label terms, safety checks, and coverage decide adoption.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eRegulators shape approval and safety rules.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003ePayers decide hospital access and uptake.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003ePricing and monitoring drive market reach.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAutolus’ Critical Delivery Network Behind AUCATZYL\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAutolus Therapeutics plc depends on GMP cell-therapy makers, specialist cancer centers, and logistics partners to move one patient’s cells from leukapheresis to infusion without losing chain-of-identity. That support matters now that AUCATZYL is approved and the company is scaling a one-dose-per-patient model.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003ePartner\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGMP manufacturers\u003c\/td\u003e\n\u003ctd\u003eAutologous batch production\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitals\u003c\/td\u003e\n\u003ctd\u003eTrial and treatment sites\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLogistics\u003c\/td\u003e\n\u003ctd\u003eCold-chain delivery\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA concise Business Model Canvas capturing Autolus Therapeutics plc’s CAR-T strategy, partners, revenue model, and key operational drivers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eQuickly spot Autolus Therapeutics’ key business-model pain points in a one-page, editable snapshot.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAutolus Therapeutics plc Reference Sources provide a trusted, traceable trail that strengthens credibility and speeds better decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eActivities\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eT-cell engineering and target design\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAutolus Therapeutics plc engineers programmed T cells to hit CD19, TRBC1, GD2, and other targets with tighter specificity in blood cancers. This work underpins 6 core programs: AUTO1, AUTO1\/22, AUTO4, AUTO6NG, AUTO8, and AUTO5.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProcess development and GMP production\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAutolus Therapeutics plc must turn each patient-specific construct into a GMP batch with vector production, cell expansion, release testing, and stability checks; in 2025, its commercial focus was AUCATZYL, so one failed lot can hit both cost and patient access. Manufacturing performance is the key driver of autologous therapy unit economics.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trial execution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAutolus Therapeutics plc runs clinical trial execution across Phase 1b\/2, Phase 1, and preclinical programs in adult ALL, pediatric ALL, PTCL, multiple myeloma, and neuroblastoma. These operations produce the safety and efficacy data regulators need for approvals, while moving multiple pipeline assets through proof-of-concept and later-stage testing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRegulatory submissions and safety monitoring\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRegulatory submissions and safety monitoring are a permanent workload for Autolus Therapeutics plc: cell therapies need pharmacovigilance, long-term follow-up, and rapid adverse-event reporting even after approval. In 2025, this matters most for AUCATZYL, where regulators expect full dossiers, safety updates, and post-treatment tracking of CRS and neurologic events.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFile regulator-ready dossiers\u003c\/li\u003e\n\u003cli\u003eTrack long-term patient safety\u003c\/li\u003e\n\u003cli\u003eReport adverse events fast\u003c\/li\u003e\n\u003cli\u003eKeep monitoring after approval\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCommercial launch and medical affairs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBy July 2026, Autolus Therapeutics plc is expected to keep building Aucatzyl in adult B-ALL after its U.S. approval in 2024, with commercial work centered on site education, payer access, and post-launch evidence. Medical affairs helps speed adoption at treatment centers, backed by the FELIX study’s 85% complete remission or CRi rate in 104 patients.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSite training for Aucatzyl use\u003c\/li\u003e\n\u003cli\u003ePayer access and reimbursement support\u003c\/li\u003e\n\u003cli\u003ePost-launch evidence generation\u003c\/li\u003e\n\u003cli\u003ePhysician adoption and readiness\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAutolus Touts AUCATZYL Launch and 85% FELIX Remission Rate\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAutolus Therapeutics plc’s key activities are engineering CAR T candidates, running GMP manufacturing for autologous batches, and advancing clinical trials across blood cancers and solid tumors. In 2025, AUCATZYL drove the commercial focus, with 104 FELIX patients showing an 85% complete remission or CRi rate.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eActivity\u003c\/th\u003e\n\u003cth\u003e2025\/2026 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAUCATZYL launch\u003c\/td\u003e\n\u003ctd\u003eU.S. commercial focus in 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFELIX efficacy\u003c\/td\u003e\n\u003ctd\u003e85% CR\/CRi in 104 patients\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline\u003c\/td\u003e\n\u003ctd\u003eAUTO1, AUTO1\/22, AUTO4, AUTO6NG, AUTO8, AUTO5\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThis Autolus Therapeutics plc Business Model Canvas preview is the exact document you’ll receive after purchase, not a sample or mockup. What you see here is a live snapshot of the final file, with the same structure, content, and formatting. Once you complete your order, you’ll unlock the full version of this same ready-to-use document for immediate download.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eResources\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProprietary programmed T-cell platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAutolus Therapeutics plc’s proprietary programmed T-cell platform is its core intangible asset, supporting antigen-specific T-cell design across multiple candidates, including its lead CAR T product AUCATZYL, approved by the U.S. FDA in 2024. It helps Autolus stand apart from standard CAR-T approaches by enabling more precise targeting and control.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAucatzyl and late-stage pipeline assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAucatzyl (obecabtagene autoleucel) is Autolus Therapeutics plc’s lead value driver and its first approved CAR-T, focused on adult relapsed\/refractory B-ALL. The broader platform adds AUTO1\/22, AUTO4, and AUTO8, giving 4 key programs in total and widening reach beyond adult ALL into other hematologic cancers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical data package\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAutolus Therapeutics plc’s clinical data package is a core asset because its trials produce the human safety and response evidence regulators, partners, and hospitals need. In the pivotal FELIX study for AUCATZYL, 77% of treated patients achieved complete remission or complete remission with incomplete hematologic recovery, with low rates of severe CRS and ICANS, which supports approval, trust, and adoption.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eManufacturing know-how and quality systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAutolus Therapeutics plc’s key resource is its GMP manufacturing know-how: each autologous CAR-T dose is made from one patient’s cells, so chain-of-identity, validated analytics, QA, and batch-release controls have to work every time. That skill set is hard to copy and expensive to build, especially when product quality can decide whether a batch is cleared or rejected.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOne patient, one bespoke batch\u003c\/li\u003e\n\u003cli\u003eGMP and QA are core barriers\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eScientific team and London headquarters\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFounded in 2014 and based in London, Autolus Therapeutics plc depends on scarce biotech talent: scientists, clinicians, and regulatory staff who can move cell therapies from lab to approval. In a clinical-stage model, human capital is the main asset, because development speed, trial quality, and launch readiness all sit with this team.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFounded: 2014\u003c\/li\u003e\n\u003cli\u003eHQ: London, UK\u003c\/li\u003e\n\u003cli\u003eCore asset: specialized biotech talent\u003c\/li\u003e\n\u003cli\u003eTeam supports R\u0026amp;D, trials, launch\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAutolus’ key edge: AUCATZYL approval and strong FELIX results\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAutolus Therapeutics plc’s key resources are its programmed T-cell platform, AUCATZYL approval, and GMP cell-therapy manufacturing know-how. The FELIX study showed 77% complete remission or CRi, while AUCATZYL was FDA-approved in 2024 for adult r\/r B-ALL.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eResource\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlatform\u003c\/td\u003e\n\u003ctd\u003eProgrammed T-cell design\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead asset\u003c\/td\u003e\n\u003ctd\u003eAUCATZYL, FDA 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical proof\u003c\/td\u003e\n\u003ctd\u003e77% CR\/CRi in FELIX\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing\u003c\/td\u003e\n\u003ctd\u003ePatient-specific GMP batches\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eValue Propositions\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOne-time targeted cell therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAutolus Therapeutics plc offers one-time autologous T-cell therapy, aiming for deep, durable remissions after a single administration instead of repeated chemotherapy. In its FELIX study, 42% of adults with relapsed or refractory B-ALL achieved complete remission with full count recovery, supporting a durable-response model in hard-to-treat disease.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFocused on high-unmet-need blood cancers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAutolus Therapeutics plc targets high-unmet-need blood cancers: relapsed or refractory ALL, pediatric ALL, PTCL, and multiple myeloma. Adult ALL alone sees roughly 70% relapse after first remission, and five-year survival in relapsed disease remains below 10% in many studies, so limited options support both urgent clinical need and strong market demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrecision targeting of disease antigens\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAutolus Therapeutics plc designs CAR-Ts around specific antigens: AUTO1 targets CD19, AUTO4 targets TRBC1, and newer programs extend to GD2 and other hematologic targets. This narrow antigen focus is meant to raise selectivity and boost therapeutic impact; AUCATZYL (obecabtagene autoleucel) was FDA-approved in 2024 for adult relapsed\/refractory B-cell precursor ALL, showing the model can reach market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBuilt for specialist treatment settings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAutolus Therapeutics plc’s cell therapy is built for specialist oncology centers, not broad primary care, so care stays with teams trained for CAR-T selection, lymphodepletion, infusion, and toxicity watch. That fits the tight logistics of a 1-time autologous treatment and helps keep patient management controlled and consistent.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExpert centers handle complex CAR-T steps\u003c\/li\u003e\n\u003cli\u003eBetter control of infusion and monitoring\u003c\/li\u003e\n\u003cli\u003eMatches Autolus Therapeutics plc logistics\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePotential to expand across multiple indications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAutolus is not tied to one cancer type: it has 1 approved CAR-T, AUCATZYL, and a pipeline spanning hematology plus solid-tumor-adjacent targets, so the same platform can add new indications over time. That broad base can lift lifecycle value and spread risk beyond a single market.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e1 approved therapy now\u003c\/li\u003e\n\u003cli\u003eMultiple next-indication programs\u003c\/li\u003e\n\u003cli\u003eBroader revenue runway\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAutolus Therapeutics: FDA-Approved CAR-T Delivering Durable Remissions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAutolus Therapeutics plc’s value proposition is a one-time CAR-T for hard-to-treat blood cancers, led by AUCATZYL, which received FDA approval in 2024 for adult relapsed\/refractory B-cell precursor ALL. In FELIX, 42% of adults with relapsed or refractory B-ALL achieved complete remission with full count recovery, backing a durable-response story. \u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAUCATZYL approval\u003c\/td\u003e\n\u003ctd\u003eFDA, 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFELIX CR with full count recovery\u003c\/td\u003e\n\u003ctd\u003e42%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCustomer Relationships\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-touch hospital onboarding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAutolus Therapeutics plc’s customer relationship is high-touch because hospitals must be trained before AUCATZYL use: leukapheresis, fludarabine\/cyclophosphamide conditioning, infusion, and 14-day post-infusion monitoring. In 2025, that made each certified transplant or cell-therapy center a consultative account, not a one-off buyer, with site readiness and staff training tied directly to product use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLong-term patient follow-up\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAutolus Therapeutics plc keeps patient ties long after infusion because CAR-T and programmed T-cell therapies can require long safety follow-up; FDA gene-therapy guidance can extend to 15 years. Patients are tracked for durable response and late events, so the relationship often runs for years, not weeks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical affairs support for physicians\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAutolus Therapeutics plc must give specialist oncologists scientific exchange, not consumer marketing, with clear dosing guidance, safety updates, and trial data for AUCATZYL, which showed 76% complete remission or CRi in its pivotal adult B-ALL study. That kind of medical affairs support is standard for regulated oncology biologics, where physician trust depends on fast, evidence-based answers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSite-level operational support\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSite-level support is critical for Autolus Therapeutics plc because each autologous CAR-T order needs tight coordination between manufacturing slots, courier timing, and patient readiness. Operational reliability shapes the customer experience: if the product is not released when the cell-therapy center is ready, treatment can slip and the one-time dose is at risk.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAlign patient readiness with product release\u003c\/li\u003e\n\u003cli\u003eCoordinate slots, shipping, and site teams\u003c\/li\u003e\n\u003cli\u003eReliability is part of the service promise\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAccess and reimbursement coordination\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAutolus Therapeutics plc must coordinate prior authorization, coding, and reimbursement fast, because broad uptake of AUCATZYL depends on hospital and payer coverage. The therapy’s FDA approval on 8 Nov. 2024 makes access work a commercial gate, not a back-office task.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCoverage must be agreed first\u003c\/li\u003e\n\u003cli\u003ePrior auth slows first use\u003c\/li\u003e\n\u003cli\u003eCorrect coding drives reimbursement\u003c\/li\u003e\n\u003cli\u003eAccess support helps sales conversion\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAutolus’ High-Touch Launch Depends on Site Readiness and Payer Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAutolus Therapeutics plc’s customer relationships are account-based and high-touch: each certified center needs training, scheduling support, and safety follow-up to deliver AUCATZYL. The 2025 commercial model depends on reliable site readiness, payer access, and tight coordination from leukapheresis to infusion.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePivotal CR\/CRi\u003c\/td\u003e\n\u003ctd\u003e76%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA approval\u003c\/td\u003e\n\u003ctd\u003e8 Nov 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePost-infusion monitoring\u003c\/td\u003e\n\u003ctd\u003e14 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eChannels\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialist treatment centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAutolus Therapeutics plc reaches patients mainly through hematology-oncology hospitals and authorized infusion centers, the only sites that can manage leukapheresis, conditioning, infusion, and follow-up for CAR-T delivery. In 2024, the FDA approved AUCATZYL, so these specialist centers are the main commercial and clinical access point for Autolus’ cell therapy patients.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trial sites\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAutolus Therapeutics plc uses multicenter oncology trial sites as its main non-commercial channel, giving patients access to cell therapy studies and producing registrational data for regulators. In 2025, this site-led model stayed central to advancing autologous CAR-T programs like AUCATZYL, where trial enrollment and follow-up also support real-world evidence after treatment.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhysician referral networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePatients usually enter Autolus Therapeutics plc through hematologists and oncologists, because relapsed B-cell malignancies like large B-cell lymphoma need specialist triage before CAR-T referral. That matters: AUCATZYL was approved in 2024 and Autolus reported 2025 launch execution, so this network now drives both trial enrollment and commercial prescribing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eScientific meetings and publications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAutolus Therapeutics plc uses congress talks and peer-reviewed papers to turn clinical data into trust, which matters in oncology because doctors, payers, and regulators want proof before adoption. In 2025, that evidence trail supported AUCATZYL's market launch and helped frame durability, safety, and response data for adult B-ALL.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBuilds clinical credibility\u003c\/li\u003e\n\u003cli\u003eSupports payer review\u003c\/li\u003e\n\u003cli\u003eRaises regulator confidence\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCommercial hospital access pathways\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFor Aucatzyl, Autolus Therapeutics plc’s commercial path runs through hospital formularies, payer reimbursement, and site-level ordering workflows. The launch hinge is execution: train 100% of target centers, secure contracting, and make product ordering fast enough for CAR-T use.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHospital formulary approval\u003c\/li\u003e\n\u003cli\u003eReimbursement setup\u003c\/li\u003e\n\u003cli\u003eSite education and ordering\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAutolus’ CAR-T launch hinges on specialist sites, referrals, and payer access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAutolus Therapeutics plc’s channels are specialist hematology-oncology centers, infusion sites, and trial hospitals; these are the only routes that can handle leukapheresis, conditioning, infusion, and follow-up for CAR-T care. In 2025, AUCATZYL launch execution made site access, payer approval, and physician referral the key commercial gate.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eRole\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialist centers\u003c\/td\u003e\n\u003ctd\u003eCommercial delivery\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial sites\u003c\/td\u003e\n\u003ctd\u003ePatient recruitment\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHematologists\u003c\/td\u003e\n\u003ctd\u003eReferral gate\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCustomer Segments\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdult relapsed or refractory B-ALL patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAdult relapsed or refractory B-ALL is Autolus Therapeutics plc’s lead commercial segment for Aucatzyl, with roughly 3,000 new U.S. adult ALL cases each year and relapse still carrying a poor prognosis; 5-year survival after relapse is often under 10%. As Autolus’ first approved product, Aucatzyl is aligned to this high-unmet-need group where salvage options remain limited.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePediatric relapsed or refractory ALL patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAutolus Therapeutics plc targets pediatric relapsed or refractory ALL, a high-need niche where AUTO1\/22 is built for children who have failed prior therapy. Pediatric ALL accounts for most childhood leukemias, and dosing plus safety must be managed very carefully in oncology trials. As a small but critical segment, it can support future label and revenue expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePeripheral T-cell lymphoma patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePeripheral T-cell lymphoma patients are a small, highly specialized segment, since PTCL makes up about 10% to 15% of non-Hodgkin lymphoma cases and remains hard to treat. Autolus Therapeutics plc’s AUTO4 targets TRBC1 in PTCL, fitting its focus on rare blood cancers where unmet need is high and the commercial pool is narrower but more defined.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMultiple myeloma patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMultiple myeloma is a large, high-value segment for Autolus Therapeutics plc: GLOBOCAN 2022 estimated about 188,000 new cases and 121,000 deaths worldwide each year, and AUTO8 is in Phase 1 for this disease. The field is crowded with CAR-Ts, bispecifics, and other immune-oncology options, but a positive AUTO8 readout could open a much bigger addressable market for the company.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~188,000 new cases globally\u003c\/li\u003e\n\u003cli\u003e~121,000 deaths globally\u003c\/li\u003e\n\u003cli\u003eAUTO8: Phase 1\u003c\/li\u003e\n\u003cli\u003eHigh competition, high upside\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNeuroblastoma and other early-stage oncology patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNeuroblastoma and other early-stage oncology patients are long-dated Customer Segments for Autolus Therapeutics plc. AUTO6NG targets GD2 in neuroblastoma, while AUTO5 is still preclinical in hematologic disease, so both add pipeline breadth beyond current lead programs and could address rare, high-unmet-need cancers with limited approved options.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGD2 target in neuroblastoma\u003c\/li\u003e\n\u003cli\u003eAUTO5 remains preclinical\u003c\/li\u003e\n\u003cli\u003eLong-dated growth segments\u003c\/li\u003e\n\u003cli\u003eDiversifies beyond lead indications\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAutolus Targets High-Need Blood Cancer Niches\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAutolus Therapeutics plc focuses on small, high-need blood cancer groups: adult relapsed or refractory B-ALL is the first commercial core for Aucatzyl, while pediatric ALL, PTCL, and multiple myeloma expand the long-term pool. These segments are defined by limited options, high relapse risk, and specialist treatment settings, so even modest uptake can matter.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eAutolus Therapeutics plc program\u003c\/th\u003e\n\u003cth\u003eWhy it matters\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAdult r\/r B-ALL\u003c\/td\u003e\n\u003ctd\u003eAucatzyl\u003c\/td\u003e\n\u003ctd\u003eFirst launch, high unmet need\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePediatric r\/r ALL\u003c\/td\u003e\n\u003ctd\u003eAUTO1\/22\u003c\/td\u003e\n\u003ctd\u003eRare, label-expansion path\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePTCL\u003c\/td\u003e\n\u003ctd\u003eAUTO4\u003c\/td\u003e\n\u003ctd\u003eSpecialized rare lymphoma\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMultiple myeloma\u003c\/td\u003e\n\u003ctd\u003eAUTO8\u003c\/td\u003e\n\u003ctd\u003eLarge, competitive upside\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eCost Structure\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and discovery spend\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAutolus Therapeutics plc keeps funding target selection, vector design, and preclinical work because pipeline growth depends on it; in biotech, early-stage science is a major fixed cost and drug development often takes 5-10 years. Industry estimates put the path from discovery to approval at over $1 billion, so this spend stays continuous, not optional.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trial operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePhase 1 and Phase 2 trials are a major cost driver for Autolus Therapeutics plc, with site payments, monitoring, data management, and long patient follow-up. Rare cancer studies are especially expensive because enrollment is narrow, so fixed trial costs are spread over fewer patients; in 2025, research and development remained the company’s biggest expense bucket.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and quality control\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAutologous cell therapy is made one patient at a time, so Materials, release testing, chain-of-identity, and cold-chain shipping all push per-batch costs up. Commercial scale-up is capital intensive because Autolus Therapeutics plc must fund GMP capacity, quality systems, and inventory control before volumes rise.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGeneral and administrative costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAutolus Therapeutics plc’s general and administrative costs cover corporate, legal, finance, and HR work, plus public-company reporting and governance. In 2025, these costs stayed tied to scale-up and commercialization, with 2025 G\u0026amp;A expense rising as the Company built the structure needed to support launch activities.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCorporate, legal, finance, HR\u003c\/li\u003e\n\u003cli\u003eSEC and governance reporting\u003c\/li\u003e\n\u003cli\u003eHigher with commercialization\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eRegulatory and post-marketing safety costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRegulatory and post-marketing safety costs stay high for Autolus Therapeutics plc because approvals need dossier work, GxP inspections, and pharmacovigilance. For CAR-T and other cell therapies, long-term follow-up can run up to 15 years, so safety monitoring does not stop at launch.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDossier prep and agency inspections\u003c\/li\u003e\n\u003cli\u003ePharmacovigilance and adverse-event reporting\u003c\/li\u003e\n\u003cli\u003e15-year follow-up for some therapies\u003c\/li\u003e\n\u003cli\u003eCosts continue across the product life cycle\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAutolus’ 2025 costs stay R\u0026amp;D-heavy, with high CAR-T manufacturing burdens\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAutolus Therapeutics plc’s cost base is still led by R\u0026amp;D, because target work, vector design, preclinical studies, and trials must keep running; in 2025, R\u0026amp;D remained the largest expense bucket. Autologous CAR-T adds one-patient manufacturing, release testing, cold-chain shipping, and GMP scale-up, so unit costs stay high.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCost item\u003c\/th\u003e\n\u003cth\u003e2025 signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003eLargest expense\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003eRose with launch buildout\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing\u003c\/td\u003e\n\u003ctd\u003eHigh per patient\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eRevenue Streams\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAucatzyl product sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAucatzyl is Autolus Therapeutics plc’s first direct product revenue and the main near-term sales driver, with uptake tied to launch execution, reimbursement, and adoption across adult B-ALL treatment centers. In 2025, its first commercial year, this stream should set the pace for near-term revenue growth if prescriptions and site openings continue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFuture sales from expanded indications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAutolus Therapeutics plc can grow revenue beyond its first approved CAR-T, AUCATZYL, by winning label expansion and new cancer approvals. With 3 named follow-on programs, AUTO1\/22, AUTO4, and AUTO8, the company has a multi-product path if trials and regulators align.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollaboration and milestone income\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAutolus Therapeutics plc can book collaboration and milestone income when partners hit development or regulatory steps, so this cash can help offset R\u0026amp;D spend. In biopharma, these receipts are usually lumpy, not recurring, and they often arrive in big steps rather than steady monthly payments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLicensing and royalty income\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIf Autolus Therapeutics plc out-licenses a platform or regional rights, it can earn upfront cash plus royalties, a common model in cell therapy deals that often use single-digit royalties and $10 million+ upfronts. That income is non-dilutive, so it can fund development without issuing more shares.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUpfront fees boost near-term cash\u003c\/li\u003e\n\u003cli\u003eRoyalties scale with sales\u003c\/li\u003e\n\u003cli\u003eLess need for equity funding\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eResearch grants and tax credits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFor Autolus Therapeutics plc, research grants and UK tax credits are non-dilutive cash sources that can cut net R\u0026amp;D spend; under the UK’s merged R\u0026amp;D regime, qualifying loss-making companies can get a 19% payable credit on eligible costs. These inflows are usually far smaller than product sales, but in a cash-burning biotech they still matter because they can fund extra trials and extend runway.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNon-dilutive funding, not equity\u003c\/li\u003e\n\u003cli\u003eUK R\u0026amp;D credit: 19%\u003c\/li\u003e\n\u003cli\u003eOffsets eligible research costs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAUCATZYL Sales Drive Autolus’ Early Revenue Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAutolus Therapeutics plc’s revenue streams are led by AUCATZYL sales, which became its first direct product revenue in 2025, plus future label expansion, partner milestones, royalties, and UK R\u0026amp;D credits. The mix is still early-stage and lumpy, but it gives the Company Name both commercial upside and non-dilutive cash support.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eStream\u003c\/th\u003e\n\u003cth\u003e2025\/2026 role\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAUCATZYL sales\u003c\/td\u003e\n\u003ctd\u003ePrimary near-term driver\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMilestones\/royalties\u003c\/td\u003e\n\u003ctd\u003eIrregular, scale with deals\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUK R\u0026amp;D credit\u003c\/td\u003e\n\u003ctd\u003e19% of eligible costs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234135843081,"sku":"autl-business-model-canvas","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/autl-business-model.webp?v=1785712092","url":"https:\/\/dcfanalyst.com\/products\/autl-business-model-canvas","provider":"DCF Analyst","version":"1.0","type":"link"}